Horizon Discovery Group PLC is a gene editing company that designs and engineers genetically-modified cells, applying them in research and clinical applications to advance human health. The Company's gene editing platform, able to alter almost any gene sequence, has generated a catalogue of over 23,000 cell and in vivo models that recapitulate the genetic anomalies found in diseases like cancer. These models have been adopted by c1,400 organizations to better understand of the genetic drivers of disease, and by Horizon in a range of services offered to customers, as well as in the Company's own research R&D pipeline.
Industry, Sector and Symbol:
- Market Cap: £211.92 million
- Outstanding Shares: 95,245,000
- 50 Day Moving Avg: GBX 252.40
- 200 Day Moving Avg: GBX 213.69
- 52 Week Range: GBX 104 - GBX 289
Sales & Book Value:
- Trailing P/E Ratio: N/A
- P/E Growth: 0.00
- Annual Revenue: £24.07 million
- Price / Sales: 8.80
- Book Value: GBX 0.82 per share
- Price / Book: 2.71
- EBIDTA: ($7,140,000.00)
- Net Margins: -39.00%
- Return on Equity: -13.64%
- Return on Assets: -12.38%
- Average Volume: 309,074 shs.
Frequently Asked Questions for Horizon Discovery Group PLC (LON:HZD)
What is Horizon Discovery Group PLC's stock symbol?
Horizon Discovery Group PLC trades on the London Stock Exchange (LON) under the ticker symbol "HZD."
Where is Horizon Discovery Group PLC's stock going? Where will Horizon Discovery Group PLC's stock price be in 2017?
5 equities research analysts have issued 1-year target prices for Horizon Discovery Group PLC's stock. Their predictions range from GBX 200 to GBX 300. On average, they anticipate Horizon Discovery Group PLC's stock price to reach GBX 233.80 in the next year. View Analyst Ratings for Horizon Discovery Group PLC.
Who are some of Horizon Discovery Group PLC's key competitors?
Some companies that are related to Horizon Discovery Group PLC include Agenus (AGEN), Arbutus Biopharma Corporation (ABUS), Corvus Pharmaceuticals (CRVS), Novavax (NVAX), NewLink Genetics Corporation (NLNK), Idera Pharmaceuticals (IDRA), Concert Pharmaceuticals (CNCE), Puretech Health PLC (PRTC), Celldex Therapeutics (CLDX), Protagonist Therapeutics (PTGX), Codexis (CDXS), Curis (CRIS), Nabriva Therapeutics AG (NBRV), Organovo Holdings (ONVO), Organovo Holdings (ONVO), Chromadex Corp (CDXC), Advaxis (ADXS) and Merrimack Pharmaceuticals (MACK).
Who are Horizon Discovery Group PLC's key executives?
Horizon Discovery Group PLC's management team includes the folowing people:
- Darrin Matthew Disley Ph.D., Chief Executive Officer, Executive Director
- Richard John Vellacott, Chief Financial Officer, Senior Vice President - Operations, Company Secretary, Executive Director
- Ian David Gilham Ph.D., Non-Executive Chairman of the Board
- Grahame David Cook, Non-Executive Director
- Susan Mary Galbraith, Non-Executive Director
- Vishal Kumar Gulati M.D., Non-Executive Director
- Jonathan Simon Milner Ph.D., Non-Executive Director
How do I buy Horizon Discovery Group PLC stock?
Shares of Horizon Discovery Group PLC and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Horizon Discovery Group PLC's stock price today?
MarketBeat Community Rating for Horizon Discovery Group PLC (LON HZD)MarketBeat's community ratings are surveys of what our community members think about Horizon Discovery Group PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Horizon Discovery Group PLC stock can currently be purchased for approximately GBX 222.50.
Consensus Ratings for Horizon Discovery Group PLC (LON:HZD) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||2 Hold Ratings, 3 Buy Ratings|
|Consensus Rating:||Buy (Score: 2.60)|
|Consensus Price Target: ||GBX 233.80|
Analysts' Ratings History for Horizon Discovery Group PLC (LON:HZD)
(Data available from 9/20/2015 forward)
|9/8/2017||Numis Securities Ltd||Reiterated Rating||Buy||GBX 300|
|7/20/2017||Royal Bank Of Canada||Boost Price Target||Speculative Buy||GBX 220 -> GBX 245|
|7/19/2017||Shore Capital||Reiterated Rating||not rated|
|6/15/2017||N+1 Singer||Boost Price Target||Buy||GBX 194 -> GBX 219|
|5/31/2017||Beaufort Securities||Reiterated Rating||Speculative Buy||GBX 200|
|5/22/2017||Panmure Gordon||Reiterated Rating||Buy||GBX 205|
Earnings History for Horizon Discovery Group PLC (LON:HZD)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Horizon Discovery Group PLC (LON:HZD)
Current Year EPS Consensus Estimate: $-8.55 EPS
Dividend History for Horizon Discovery Group PLC (LON:HZD)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Horizon Discovery Group PLC (LON:HZD)Insider Trades by Quarter for Horizon Discovery Group PLC (LON:HZD)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|12/2/2016||Susan Searle||Insider||Buy||10,000||GBX 118||£11,800|
|11/12/2015||Milner,Jonathan Simon||Insider||Buy||7,500||GBX 141||£10,575|
Headline Trends for Horizon Discovery Group PLC (LON:HZD)
Latest Headlines for Horizon Discovery Group PLC (LON:HZD)
Horizon Discovery Group PLC (HZD) Chart for Wednesday, September, 20, 2017